Biostem Technologies (BSEM) Company presentation summary

Mission and vision

• Aims to deliver the most advanced wound healing technologies globally, focusing on regenerative medicine and perinatal tissue allografts.

• Pursues innovation to improve patient outcomes and quality of life.

Market opportunity and growth strategy

• Targets a $23B US soft tissue allograft market, spanning orthopedics, wound care, spine, urology, and women’s health.

• Expanding into hospital settings and new patient populations to diversify revenue and payer coverage.

• Growth driven by acquisitions, new product launches, and expanding the commercial team.

• Leveraging GPO contracts and a national sales force to broaden commercial reach.

Product portfolio and technology

• Offers six perinatal-derived allograft brands, including newly acquired Neox and Clarix families.

• Proprietary technologies: BioRetain, CryoTek, and SteriTek, preserving natural tissue properties for superior healing.

• Pipeline includes a pending 510(k) clearance for a Flo-based product.

• Over 90 clinical publications support product efficacy.